New Findings on Brain Cell Death in Dementia Research

To tackle Alzheimer’s disease and various forms of dementia, it’s crucial to grasp how these conditions damage the brain. This includes understanding how toxic proteins accumulate within neurons, ultimately leading to their demise.

Cells can perish through several mechanisms, one of which is apoptosis—a process the body employs to eliminate waste. However, this doesn’t fully explain the cell death observed in neurodegenerative diseases.

A recent study published in Nature Communications, led by researchers from King’s College London, highlights a potentially significant factor known as karyoptosis, characterized by the degeneration of a cell’s nucleus.

Building on prior studies, the team discovered that karyoptosis occurs when harmful substances within cells accumulate faster than they can be cleared away. They also identified key elements of this process that could present new targets for treatments.

“The loss of brain cells contributes significantly to the symptoms faced by individuals with dementia,” says neuroscientist Rebecca Casterton from King’s College London. “Our study reveals a new series of chemical interactions that can orchestrate cell death in brain cells.”

In experiments using brain cells from humans and rats, researchers found that hindering the waste removal processes in neurons—prompting protein build-up—triggered a specific chemical reaction. This process involved an enzyme called p38 MAP kinase, which marks a vital structural protein, LaminB1, for destruction. This has severe consequences for cortical neurons, leading to the nucleus’s disintegration and collapse.

Intriguingly, when p38 MAPK was inhibited, while toxic protein levels remained unchanged, the breakdown of the nucleus and subsequent cell death were markedly delayed.

“By targeting the interaction between p38 MAP kinase and LaminB1, we might slow down cell death, buying time for more focused therapies for particular neurodegenerative diseases,” says functional genomicist Manolis Fanto from King’s College London.

Additionally, analysis of 3,000 brain cells from 28 patients who had died from either frontotemporal dementia or Alzheimer’s disease revealed that 35 percent of cells in the frontal cortex exhibited signs of karyoptosis—compared to only 15 percent in age-matched healthy controls.

“Karyoptosis may account for a significant degree of neuronal degeneration and cell death in the types of dementia we studied,” the researchers noted in their published paper.

Next, it’s essential to conduct experiments that target the enzyme and protein interactions identified as central to karyoptosis. This could reveal more about potential treatments.

Dementia encompasses various forms, influenced by a host of processes and risk factors. Its complexity often complicates understanding and treatment. Still, even if karyoptosis only explains some cell deaths in certain dementia cases, it seems to be a key player linking dementia to neuron decay. Preventing or delaying this decay could lead to significant improvements.

“For years, we’ve recognized the accumulation of toxic proteins in Alzheimer’s disease and frontotemporal dementia, but the exact mechanisms behind cell loss have been unclear,” mentions Sara Rodrigues, senior research manager at Alzheimer’s Research UK, which supported the study. “Finding karyoptosis is a pivotal move toward identifying treatment targets that might halt or slow cell loss, moving us closer to a potential cure for dementia.”

The research has been published in Nature Communications.